Annual cost of stable coronary artery disease in France: A modeling study

Autor: Olivier Dubourg, Kevin Zarca, Nicolas Danchin, Thibaut Caruba, Brigitte Sabatier, Karine Chevreul, Benjamin Cadier, Yves Juillière
Jazyk: angličtina
Předmět:
Male
Médicaments
Time Factors
National Health Programs
Cost-Benefit Analysis
medicine.medical_treatment
Coronary artery disease
Recurrence
Models
Cause of Death
Myocardial infarction
Coronary Artery Bypass
Cause of death
Drug-Eluting Stents
Health Care Costs
General Medicine
Middle Aged
Models
Economic
Treatment Outcome
surgical procedures
operative
Metals
Cardiology
Female
Stents
France
Costing study
Drug
Cardiology and Cardiovascular Medicine
medicine.medical_specialty
Revascularisation
Prosthesis Design
Revascularization
Drug Costs
Coûts
Percutaneous Coronary Intervention
Cost Savings
Internal medicine
medicine
Humans
Angina
Stable
cardiovascular diseases
Aged
Angor stable
business.industry
Percutaneous coronary intervention
Stent
Cardiovascular Agents
medicine.disease
Modélisation
Chronic Disease
Cardiovascular agent
Emergency medicine
Conventional PCI
Health Expenditures
business
Zdroj: Archives of Cardiovascular Diseases. (11):576-588
ISSN: 1875-2136
DOI: 10.1016/j.acvd.2015.06.006
Popis: Background Few studies have analyzed the cost of treatment of chronic angina pectoris, especially in European countries. Aim To determine, using a modeling approach, the cost of care in 2012 for 1 year of treatment of patients with stable angina, according to four therapeutic options: optimal medical therapy (OMT); percutaneous coronary intervention with bare-metal stent (PCI-BMS); PCI with drug-eluting stent (PCI-DES); and coronary artery bypass graft (CABG). Methods Six different clinical scenarios that could occur over 1 year were defined: clinical success; recurrence of symptoms without hospitalization; myocardial infarction (MI); subsequent revascularization; death from non-cardiac cause; and cardiac death. The probability of a patient being in one of the six clinical scenarios, according to the therapeutic options used, was determined from a literature search. A direct medical cost for each of the therapeutic options was calculated from the perspective of French statutory health insurance. Results The annual costs per patient for each strategy, according to their efficacy results, were, in our models, € 1567 with OMT, € 5908 with PCI-BMS, € 6623 with PCI-DES and € 16,612 with CABG. These costs were significantly different (P
Databáze: OpenAIRE
Externí odkaz: